{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T14:45:38Z","timestamp":1720190738436},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["psy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.psychres.2017.12.089","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T08:34:19Z","timestamp":1514968459000},"page":"248-252","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders"],"prefix":"10.1016","volume":"261","author":[{"given":"Huiqiong","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyajit","family":"Mohite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Suchting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaoluwa O.","family":"Okusaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2017.12.089_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15563650.2017.1287373","article-title":"Analytical confirmation of synthetic cannabinoids in a cohort of 179 presentations with acute recreational drug toxicity to an Emergency Department in London, UK in the first half of 2015","volume":"55","author":"Abouchedid","year":"2017","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.psychres.2017.12.089_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2578","article-title":"Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: a multicenter-observational study","volume":"32","author":"Acciavatti","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2017.12.089_bib3","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2147\/NDT.S107622","article-title":"Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients","volume":"12","author":"Altintas","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.psychres.2017.12.089_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1465-3362.2012.00519.x","article-title":"Patterns of synthetic cannabinoid use in Australia","volume":"32","author":"Barratt","year":"2013","journal-title":"Drug Alcohol Rev."},{"key":"10.1016\/j.psychres.2017.12.089_bib5","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/0269881116658990","article-title":"Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis","volume":"30","author":"Bassir Nia","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2017.12.089_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0021917","article-title":"Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity","volume":"6","author":"Brents","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2017.12.089_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.psychres.2017.12.089_bib8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08897077.2014.959151","article-title":"Synthetic cannabinoids: use and predictors in a community sample of young adults","volume":"36","author":"Caviness","year":"2015","journal-title":"Subst. Abus."},{"key":"10.1016\/j.psychres.2017.12.089_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/15504263.2014.929364","article-title":"Use of synthetic cannabinoids in patients with psychotic disorders: case series","volume":"10","author":"Celofiga","year":"2014","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.psychres.2017.12.089_bib10","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1124\/dmd.112.047530","article-title":"Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2\/Spice: identification of novel cannabinoid receptor ligands","volume":"40","author":"Chimalakonda","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.psychres.2017.12.089_bib11","first-page":"1","article-title":"Synthetic cannabinoid use in an acute psychiatric inpatient unit","author":"Clancy","year":"2017","journal-title":"Int. J. Ment. Health Nurs."},{"key":"10.1016\/j.psychres.2017.12.089_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bjp.0705666","article-title":"The endocannabinoid system: a general view and latest additions","volume":"141","author":"De Petrocellis","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.psychres.2017.12.089_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1176\/appi.ps.53.7.861","article-title":"Medical morbidity, mental illness, and substance use disorders","volume":"53","author":"Dickey","year":"2002","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.psychres.2017.12.089_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drugalcdep.2011.01.012","article-title":"Synthetic cannabinoid JWH-018 and psychosis: an explorative study","volume":"117","author":"Every-Palmer","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.psychres.2017.12.089_bib15","doi-asserted-by":"crossref","unstructured":"Falk, C.F., Biesanz, J.C., 2016. Two Cross-Platform Programs for Inferences and Interval Estimation About Indirect Effects in Mediational Models [WWW Document]. SAGE Open. URL \u3008http:\/\/sgo.sagepub.com\/lookup\/doi\/10.1177\/2158244015625445\u3009.","DOI":"10.1177\/2158244015625445"},{"key":"10.1016\/j.psychres.2017.12.089_bib16","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders","author":"First","year":"1995"},{"key":"10.1016\/j.psychres.2017.12.089_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3949\/ccjm.79a.11147","article-title":"Synthetic legal intoxicating drugs: the emerging \u201cincense\u201d and \u201cbath salt\u201d phenomenon","volume":"79","author":"Jerry","year":"2012","journal-title":"Clevel. Clin. J. Med."},{"key":"10.1016\/j.psychres.2017.12.089_bib18","series-title":"Monitoring the Future National Results on Drug Use 1975\u20132013: 2013 Overview, Key Findings on Adolescent Drug use","author":"Johnston","year":"2014"},{"key":"10.1016\/j.psychres.2017.12.089_bib19","series-title":"Increase in Synthetic Cannabinoid (K2)-Related Adverse Events and Emergency Department Visits, New York City","author":"Kunins","year":"2015"},{"key":"10.1016\/j.psychres.2017.12.089_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drugpo.2017.05.007","article-title":"Increased in synthetic cannabinoids-related harms: results from a longitudinal web-based content analysis","volume":"44","author":"Lamy","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.psychres.2017.12.089_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1082-989X.7.1.83","article-title":"A comparison of methods to test mediation and other intervening variable effects","volume":"7","author":"MacKinnon","year":"2002","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.psychres.2017.12.089_bib22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/10826084.2016.1263663","article-title":"Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting","volume":"52","author":"Manseau","year":"2017","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.psychres.2017.12.089_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(97)01560-4","article-title":"Characterization of the acute endocrine actions of (-)-11-hydroxy-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210), a potent synthetic cannabinoid in rats","volume":"344","author":"Mart\u00edn-Calder\u00f3n","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.psychres.2017.12.089_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/hup.2586","article-title":"Substance-related psychopathology and aggressiveness in a nightlife holiday resort: results from a pilot study in a psychiatric inpatient unit in Ibiza","volume":"32","author":"Martinotti","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2017.12.089_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/815424","article-title":"Research article: novel psychoactive substances in young adults with and without psychiatric comorbidities","volume":"2014","author":"Martinotti","year":"2014","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.psychres.2017.12.089_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/1871527316666170413101839","article-title":"Synthetic cannabinoids: psychopharmacology, clinical aspects, psychotic onset","volume":"16","author":"Martinotti","year":"2017","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.psychres.2017.12.089_bib27","series-title":"Mplus User's Guide","author":"Muth\u00e9n","year":"2012"},{"key":"10.1016\/j.psychres.2017.12.089_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/00952990.2015.1106551","article-title":"Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011\u20132014","volume":"42","author":"Palamar","year":"2016","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.psychres.2017.12.089_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.psychres.2013.08.043","article-title":"Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort","volume":"210","author":"Picci","year":"2013","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2017.12.089_bib30","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2017.12.089_bib31","doi-asserted-by":"crossref","unstructured":"Satorra, A., 2000. Scaled and adjusted restricted tests in multi-sample analysis of moment structures. In: Innovations in Multivariate Statistical Analysis. A Festschrift for Heinz Neudecker. Kluwer Academic Publishers, London, pp. 233\u2013247.","DOI":"10.1007\/978-1-4615-4603-0_17"},{"key":"10.1016\/j.psychres.2017.12.089_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2011.04.011","article-title":"The impact of substance use disorders on the course of schizophrenia-A 15-year follow-up study. Dual diagnosis over 15 years","volume":"130","author":"Schmidt","year":"2011","journal-title":"Schizophrenia Res."},{"key":"10.1016\/j.psychres.2017.12.089_bib33","doi-asserted-by":"crossref","first-page":"e2606","DOI":"10.1002\/hup.2606","article-title":"The risk of violence associated with novel psychoactive substance misuse in patients presenting to acute mental health services","volume":"32","author":"Shafi","year":"2017","journal-title":"Hum. Psychopharmacol.: Clin. Exp."},{"key":"10.1016\/j.psychres.2017.12.089_bib34","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2307\/270723","article-title":"Asymptotic confidence intervals for indirect effects in structural equation models","volume":"13","author":"Sobel","year":"1982","journal-title":"Sociol. Methodol."},{"key":"10.1016\/j.psychres.2017.12.089_bib35","series-title":"Using Multivariate Statistics","author":"Tabachnick","year":"2001"},{"key":"10.1016\/j.psychres.2017.12.089_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1505328","article-title":"Synthetic cannabinoid\u2013related illnesses and deaths","volume":"373","author":"Trecki","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2017.12.089_bib37","series-title":"World Drug Report 2015","author":"United Nations Office on Drugs and Crime","year":"2015"},{"key":"10.1016\/j.psychres.2017.12.089_bib38","series-title":"World Drug Report 2016","author":"United Nations Office on Drugs and Crime","year":"2016"},{"key":"10.1016\/j.psychres.2017.12.089_bib39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","article-title":"A survey study to characterize use of Spice products (synthetic cannabinoids)","volume":"120","author":"Vandrey","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.psychres.2017.12.089_bib40","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00216-010-4171-0","article-title":"In vitro phase i metabolism of the synthetic cannabimimetic JWH-018","volume":"398","author":"Wintermeyer","year":"2010","journal-title":"Anal. Bioanal. Chem."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117311101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178117311101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T23:37:39Z","timestamp":1570577859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178117311101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":40,"alternative-id":["S0165178117311101"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2017.12.089","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2017.12.089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}